A new class of therapeutics known as "digital therapeutics" (DTx) has been made possible by the evolution and widespread adoption of technology, specifically in the areas of artificial intelligence, deep learning, and health monitoring using wearables, changing medical protocols, the need to reduce costs, and these factors are all influencing to the transformation of healthcare.

The global digital therapeutics market pegged at $ 2.2 billion (2020) is set to gain momentum. The next phase of expansion is probably going to be fueled by expanding pharma-digital therapeutic alliances, increasing focus of digital therapeutics companies on mental health, psychiatric conditions, and cognitive impairments, gradually improving reimbursement situations, a favorable funding environment, and a strong pipeline of digital therapeutics products.